With equity markets reeling due to President Donald Trump's tariffs, many investors are taking this opportunity to buy shares ...

Control-IQ+, compatible with both the t:slim X2 insulin pump and Tandem Mobi System, is now available for people with type 1 diabetes ages 2 years and older and adults with type 2 diabetes.

AID systems, which pair a glucose sensor with a pump to automate insulin dosing, are covered by Medicare and many private insurers in the U.S. for people with Type 1 diabetes. Tandem currently has ...

In this episode of Vanguards of Health Care, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview about Tandem’s Mobi pump, designed for discretion and simplicity, and the ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $35.11, a high ...

Mizuho initiated coverage of Tandem Diabetes (TNDM) with a Neutral rating and $20 price target The firm’s neutral stance reflects both the ...

Tandem Diabetes (TNDM) announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company’s advanced ...

The Control-IQ+ algorithm enables AID in conjunction with Tandem’s t:slim X2 and Mobi insulin pumps and a compatible continuous glucose monitor (CGM). The updated algorithm allows for a wider ...

The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is ...